Mesoblast's cell therapy shows encouraging results in mid-stage arthritis …

Mesoblast's cell therapy shows encouraging results in mid-stage arthritis …

Thinly traded micro cap Mesoblast Limited (MESO +8.9%) heads north on light volume in response to its announcement of positive interim results from a Phase 2 clinical trial assessing its cell therapy for the treatment of patients with rheumatoid

(Visited 3 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.